WuXi AppTec provides R&D & manufacturing services enabling companies in the pharmaceutical & biotech industries worldwide to advance discoveries.
Here is the table with the provided content formatted for easy readability:
| Category | Details |
|---|---|
| Contact Us | EN |
| About Us | |
| Services | |
| Platform | |
| News | |
| Careers | |
| Investors | |
| SEE MORE | SEE MORE |
| Financial Results Q3 2024 | Despite external challenges, WuXi AppTec revenue and profit continued to grow QoQ in the first three quarters of 2024. |
| Revenue (Q3 2024) | Back to RMB 10+ Billion, up 14.6% YoY excluding COVID-19 commercial projects. |
| Backlog (Q3 2024) | Backlog up 35.2% YoY. |
| Date | October 28, 2024 |
| Company Overview | WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company providing a broad portfolio of R&D and manufacturing services in the pharmaceutical and life sciences industry. |
| Financial Results H1 2024 | Despite external challenges, WuXi AppTec maintained stable operations in the first half of 2024. |
| Revenue (Q2 2024) | Revenue reached RMB 9,259 Million in the second quarter, up 0.3% YoY excluding COVID-19 commercial projects. |
| Net Profit (H1 2024) | Net profit attributable to the owners of the company reached RMB 4,240 Million, with diluted earnings per share (EPS) of RMB 1.45 for the first half. |
| Adjusted Non-IFRS Net Profit (H1 2024) | Adjusted Non-IFRS net profit attributable to the owners of the company reached [data missing]. |
| Revenue (H1 2024) | Revenue reached RMB 17,241 Million for the first half, down 0.7% YoY excluding COVID-19 commercial projects. |
| MSCI ESG Rating | WuXi AppTec maintains AA MSCI ESG rating for the fourth consecutive year. |
| Date | September 1, 2024 |
| MSCI ESG Rating Details | The rating reflects WuXi AppTec’s commitment to incorporating environmental and social responsibilities into business strategies and operations. |
| Read More |
This table organizes the content as requested while maintaining the original text without modification. You can use this directly for your needs.
-
域名信息
注册人/机构：Network Solutions,LLC
注册人邮箱：-
域名年龄：16年8个月30天（过期时间为2028年02月12日)
-
备案信息
备案号：沪ICP备10016157号
名称：上海药明康德新药开发有限公司
性质：企业
审核时间：2024-09-02
-
网站信息
IP：47.111.33.220[中国浙江杭州 阿里云]
排行
#40131 访问次数
- 预估流量
热门关键词
- 全球
- 桌面端
国家&地区分布图
- 仅限桌面
流量来源
- 全球
- 仅限桌面端
数据统计
数据评估
本站血鸟导航提供的Home相关数据内容都来源于网络或站长收集，不保证外部链接和内容的准确性和完整性，同时，对于该外部链接的指向，不由血鸟导航实际控制，在2024年11月17日 下午11:42收录时，该网页上的内容，都属于合规合法，后期网页的内容如出现违规或不对称，欢迎联系我们邮箱进行删除或更改，血鸟导航不承担任何责任。
相关导航
赣公网安备36020002000448号